Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso

Journal of Medical Virology

Volumn 78, Issue 11, 2006, Pages 1385-1391

  Nadembega, W M ^a,b   Giannella, S ^c   Simpore, J ^a,b,c   Ceccherini Silberstein, F ^c   Pietra, V ^a   Bertoli, A ^c   Pignatelli, S ^a   Bellocchi, M C ^d   Nikiema, J B ^b   Cappelli, G ^c   Bere, A ^b   Colizzi, V ^c   Perno, C P ^c,d   Musumeci, S ^e  

^a Centre Médical Saint Camille de Ouagadougou CMSC   (Burkina Faso)

^b UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

Author keywords

ARV; Burkina Faso; Drug resistance; Genotype; HIV 1; Vertical transmission

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BURKINA FASO; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DEVELOPING COUNTRY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; PHYLOGENY; PRESCHOOL CHILD; SINGLE DRUG DOSE; STRUCTURAL GENE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKINA FASO; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; PHYLOGENY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33749549743     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20709     Document Type: Article

References (34)

1. Ahmadou A, François D, Dequae-Merchadou L, Haverkamp G, Hudgens M, Hughes J, Karon J, Leroy V, Newell ML, Richardson B, Wevorling GJ. 2001. Estimating the efficacy of interventions to prevent mother-to-child transmission of HIV in breast-feeding populations: Development of a consensus methodology. Stat Med 23:3539-3556.
2. Bellocchi MC, Forbid F, Palombi L, Gori C, Coelho E, Svicher V, D'Arrigo R, Emberti-Gialloreti L, Ceffa S, Erba F, Marazzi MC, Ceccherini Silberstein F, Perno CF. 2005. Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: Results from the DREAM Programme. J Med Virol 76:452-8.
3. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1-F5.
4. Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, Vella S, Curry R, Robinson P, Lange JMA, Montaner JSG. 2001. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 15:1269-1274.
5. Delaugerre C, Mouroux M, Yvon-Groussin A, Simon A, Angleraud F, Huraux J-M, Agut H, Katlama C, Calvez V. 2001. Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice. Antimicrob Agents Chemother 45:946-948.
6. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB. 2001. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15:1951-7.
7. Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, Weber JN. 2002. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 16:1139-1146.
8. Holguin A, Alvarez A, Soriano V. 2002. High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS 16:1163-1170.
9. ème rapport mondial. UNAIDS Geneva Switzerland.
10. Kandathil AJ, Ramalingam S, Kannangai R, David S, Sridharan G. 2005. Molecular epidemiology of HIV. Indian J Med Res 121:333-344.
11. Kantor R. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. Plos Med 2:325-337.
12. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras TR. 1996. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 2:753-9.
13. Milinlovic A, Martinez E. 2004. Nevirapine in the treatment of HIV. Expert Rev Anti Infect Ther 2:367-373.
14. Montes B, Vergne L, Peeters M, Reynes J, Delaporte E, Segondy M. 2004. Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J AIDS 35:329-336.
15. Nguyen VK, Grennan T, Peschard K, Tan D, Tiendrebeogo I. 2003. Antiretroviral use in Ouagadougou, Burkina-Faso. AIDS 17:S109-S111.
16. Nkengasong JN, Adje-Toure C, Weidle PJ. 2004. HIV antiretroviral drug resistance in Africa. AIDS 6:4-12.
17. Oelrichs RB, Workman C, Laukkanen T, McCutchan FE, Deacon NJ. 1998. A novel subtype A/G/J recombinant full-length HIV type 1 genome from Burkina Faso. AIDS Res Hum Retroviruses 14:1495-1500.
18. Ouédraogo-Traoré R, Montavon C, Sanou T, Vidal N, Sangaré L, Sanou I, Soudré R, Mboup S, Delaporte E, Peeters M. 2003. CRF06_cpx is the predominant HIV-1 variant in AIDS patients from Ouagadougou, the capital city of Burkina-Faso. AIDS 17:441-444.
19. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Sattien GA, Aschman D, Holmberg SD, and the HIV Outpatient Study Investigators. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med 338:853-860.
20. Papathanasopoulos MA, Hunt GM, Tiemesse CT. 2003. Evolution and Diversity of HIV-1 in Africa-a review. Virus Genes 26:151-163.
21. Peeters M. 2000. Recombinant HIV sequences: Their role in the global epidemic. In: Kuiken CL, Foloy B, Hahn B, Korber B, McCutchan F, Marx PA, Mellors JW, Mullins JI, Sodroski J, Wolinksy S, editors. In HIV sequence compendium 2000. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, pp I-39-I-54.
22. Peeters M, Toure-Kane C, Nkengasong JN. 2003. Genetic diversity of HIV in Africa: Impact on diagnosis, treatment, vaccine development and trials. AIDS 17:2547-2560.
23. Pignatelli S, Simpore J, Pietra V, Ouedraogo L, Conombo G, Saleri N, Pizzocolo C, Tall F, Ouiminga A, Castelli F, Carosi G. 2005. Factors predicting uptake to Voluntary Counselling and Testing (VCT) in a real life setting in a mother and child center in Ouagadougou (Burkina Faso). A two-year experience. Trop Med Int Health 44:350-357.
24. Rapport Ministère de la Santé du Burkina Faso. 2003. Rapport de l'Atelier sur la production des estimations de la prévalence du VIH et des cas de SIDA 2002 au Burkina Faso. Kaya 24-25 November 2003.
25. Romano L, Venturi G, Bloor S, Harrigan R, Larder BA, Major JC, Zazzi M. 2002. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J Infect Dis 185:898-904.
26. Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. 1995. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis 172:70-80.
27. Shafer RW, Dupnik K, Winters MA, Eshlemann SH. 2001. HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors JW, Wolinsky S, Korber B, editors. In HIV sequence compendium 2001. Los Alamos, NM, LA-UR 02-2877: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, pp 83-133.
28. Simpore J, Pietra V, Savadogo A, Pignatelli S, Nikiema JB3, Nadembega WMC, Yara J, Zoungrana N, Bakouan D, Colizzi V, Castelli F, Musumeci S. 2006. Reduction of mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso. J Med Virol 78:148-152.
29. Stoeckli TC, MaWhinney S, Uy J, Duan C, Lu J, Shugarts D, Kuritzkes DR. 2002. Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine. Antimicrob Agents Chemother 46:4000-4003.
30. UNAIDS/WHO. 2004. Epidemiological fact sheet on HIV/AIDS and sexually transmitted infections: Burkina-Faso, 2004 Update p 1-15.
31. Vergne L, Toure-Kane C, Laurent C, Diakhate N, Ngom Nueye FN, Gueye PM, Sow PS, Faye MA, Liegeois F, Ndir A, Laniece I, Peeters M, Ndoye I, Mboup S, Delaporte E. 2003a. Low rate of genotypic HIV-1 drug resistance strains in the Senegalese government initiative access to antiretroviral therapy. AIDS 17:S31-S38.
32. Vergne L, Paraskevis D, Vandamme A-M, Delaporte E, Peeters M. 2003b. High prevalence of CRF02_AG and many minor resistance-related mutations at the protease gene among HIV-infected treatment-naive immigrants in Madrid. AIDS 17:1105-1107.
33. Wainberg MA. 2004a. The emergence of HIV resistance and new antiretrovirals: Are we winning? Drug Resist Updat 7:163-167.
34. Wainberg MA. 2004b. HIV-1 subtype distribution and the problem of drug resistance. AIDS 18:S63-S68.